Therapeutic Potential of Inulin‐Coated MCT Microcapsules in Modulating the Gut Microbiome for Effective Treatment of Diet‐Induced Obesity DOI Creative Commons
Amin Ariaee, Hannah R. Wardill, Anthony Wignall

et al.

Advanced Therapeutics, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 9, 2024

Abstract Obesity, a global epidemic, leads to metabolic dysregulation and systemic inflammation. Recently, therapies targeting the gut microbiome have garnered attention for health regulation. This study evaluates potential of inulin‐coated medium‐chain triglyceride (InuMCT) microcapsules in rats with diet‐induced obesity (DIO). Inulin prebiotic fibers been shown promote microbiome, while digestion products medium chain triglycerides (MCTs), free fatty acids, mono‐/diglycerides, can attenuate pro‐inflammatory outcomes. It is hypothesized that encapsulating MCTs within inulin via spray drying creates solid dosage form exert multifunctional effects ameliorating inflammation DIO. InuMCT treatments not only reduce DIO weight gain but also improve markers high‐fat diet (HFD) fed rats. Specifically, attenuates reduction high‐density lipoprotein (HDL) by 55% lowers glucose levels 21%. Meanwhile, increases HDL 23% reduces 15%. Furthermore, decreases serum proinflammatory tumor necrosis factor‐alpha (TNF‐α) 35%, further TNF‐α normal 21 days. These results highlight InuMCT's superior efficacy, offering promising strategy combating related diseases.

Language: Английский

Engineered inulin-based hybrid biomaterials for augmented immunomodulatory responses DOI
Ashok Kumar Jangid,

Kyung Mu Noh,

Sung Jun Kim

et al.

Carbohydrate Polymers, Journal Year: 2024, Volume and Issue: 340, P. 122311 - 122311

Published: May 23, 2024

Language: Английский

Citations

5
Future Prospects in Inulin Research DOI
Akshay Kumar Lunawat, Nikhar Vishwakarma, Sarjana Raikwar

et al.

Published: Jan. 1, 2025

Language: Английский

Citations

0
An instant polymer “coffee”: Facilitating the dissolution of high-molecular-weight water-soluble polymers DOI
Shiyuan Wang, Zhenghua Sun,

Xiaoqin Cao

et al.

Polymer, Journal Year: 2025, Volume and Issue: unknown, P. 128300 - 128300

Published: March 1, 2025

Language: Английский

Citations

0
Translational strategies for oral delivery of faecal microbiota transplantation DOI
Srinivas Kamath, Robert V. Bryant, Samuel P. Costello

et al.

Gut, Journal Year: 2025, Volume and Issue: unknown, P. gutjnl - 335077

Published: April 29, 2025

Faecal microbiota transplantation (FMT) has emerged as a transformative therapy for Clostridioides difficile infections and shows promise various GI systemic diseases. However, the poor patient acceptability accessibility of ‘conventional’ FMT, typically administered via colonoscopies or enemas, hinders its widespread clinical adoption, particularly chronic conditions. Oral administration FMT (OralFMT) overcomes these limitations, yet faces distinct challenges, including significant capsule burden, palatability concerns microbial viability during gastric transit. This review provides comprehensive analysis emerging strategies that aim to advance OralFMT by: (1) refining processing technologies (eg, lyophilisation) enable manufacturing low-volume formulations reducing burden (2) developing delivery improve organoleptic safeguard targeted colonic release. These advancements present opportunities expand therapeutic scope, beyond C. infections, towards conditions requiring frequent dosing regimens. While this primarily focuses on optimising delivery, it is important contextualise within broader shift defined consortia. Live biotherapeutic products (LBPs) offer an alternative approach, interplay between LBPs in practice remains unresolved. We postulate continued innovation multidisciplinary approach can further increase efficacy scalability by enabling disease site targeting, co-delivery compounds overcoming colonisation resistance. Realising goals positions cornerstone personalised care across range diseases rooted microbiome health.

Language: Английский

Citations

0
Microbiome-driven precision medicine: Advancing drug development with pharmacomicrobiomics DOI
Negar Ebadpour, Mohammad Abavisani, Amirhossein Sahebkar

et al.

Journal of drug targeting, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 27

Published: May 19, 2025

Pharmacomicrobiomics investigates the complicated relationship between gut microbiome and medications, highlighting how affects drug absorption, metabolism, overall treatment outcomes. The interaction pharmaceutical agents host microbiota is inherently bidirectional complex. While administration of various drugs can alter composition diversity microbial community, intestinal microbiota, in turn, plays a crucial role modulating fundamental pharmacokinetic pharmacodynamic processes, which turn affect efficacy safety drugs. Microbial communities influence metabolism many medications two primary ways: directly indirectly. Direct mechanisms typically entail induction biochemical alterations multiple transformations on drug, whereas indirect encompass modifications synthesis metabolites, interactions with immune system, indirectly drug's efficacy. For instance, play an important part activating prodrugs like sulfasalazine, improving outcomes immunotherapy, minimizing toxicity through specific interventions. Nonetheless, barriers also emerge from breakdown reducing their therapeutic efficacy, along adverse reactions mediated by microbiota. Innovations probiotics, fecal transplantation, profiling have shown promise enhancing these interactions. Utilizing distinct individuals, pharmacomicrobiomics offers route to personalized, precise, safer therapies, signaling evolution development clinical practice. This study aims provide comprehensive overview microbiome-drug interactions, particular focus highlight potential revolutionize precision medicine.

Language: Английский

Citations

0
A critical need for ‘gut neutrality’: mitigating adverse drug-microbiome interactions DOI
Srinivas Kamath, Paul Joyce

Expert Opinion on Drug Metabolism & Toxicology, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 19, 2024

Language: Английский

Citations

2
Prebiotic Supplementation Modulates the Gut Microbiome for Improving Oral Antipsychotic Bioavailability DOI Creative Commons
Kate Collins, Srinivas Kamath, Tahlia R. Meola

et al.

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: July 19, 2024

Atypical antipsychotics are crucial for the management of schizophrenia and bipolar disorder, yet they exhibit significant pharmacokinetic variability which leads to inconsistent therapeutic responses. This study investigates hypothesis that gut microbiome composition critically influences oral bioavailability lurasidone, a poorly soluble weak base antipsychotic with pH-dependent solubility. To investigate this, male Sprague-Dawley rats underwent systematic manipulation through pretreatment antibiotics or prebiotics (inulin) 14 days prior single dose lurasidone. Pharmacokinetic analysis collected plasma samples revealed 4.3-fold increase in lurasidone following prebiotic pretreatment, compared control (no pretreatment) group. Conversely, was highly variable depleted (i.e., antibiotic treatment group), 80% animals demonstrating lower than Characterisation short-chain fatty acid (SCFA) concentrations demonstrated positive correlations between bioavailability, microbial diversity, SCFA levels, mediated by modulation luminal pH. Elevated levels created favourable environment solubilisation lowering intestinal These findings highlight potential optimising pharmacokinetics personalised interventions. Furthermore, correlation SCFAs suggests their as biomarkers predicting inter-patient variability, particularly bases. Thus, new avenues opened developing novel co-therapies screening tools enhance performance, potentially improving outcomes patients disorder.

Language: Английский

Citations

1
Enhancing the pharmacokinetics of abiraterone acetate through lipid-based formulations: addressing solubility and food effect challenges DOI
Ali Taheri, Ruba Almasri, Anthony Wignall

et al.

Drug Delivery and Translational Research, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 29, 2024

Language: Английский

Citations

1
Contrasting the pharmacokinetic performance and gut microbiota effects of an amorphous solid dispersion and lipid nanoemulsion for a poorly water-soluble anti-psychotic DOI Creative Commons
Tahlia R. Meola, Srinivas Kamath, Aurelia S. Elz

et al.

European Journal of Pharmaceutics and Biopharmaceutics, Journal Year: 2024, Volume and Issue: 203, P. 114453 - 114453

Published: Aug. 10, 2024

Increasing attention is being afforded to understanding the bidirectional relationship that exists between oral drugs and gut microbiota. Often overlooked, however, impact pharmaceutical excipients exert on Subsequently, in this study, we contrasted pharmacokinetic performance microbiota interactions two commonly employed formulations for poorly soluble compounds, namely 1) an amorphous solid dispersion (ASD) stabilised by poly(vinyl pyrrolidone) K-30, 2) a lipid nanoemulsion (LNE) comprised of medium chain glycerides lecithin. The antipsychotic, lurasidone, was formulated with ASD LNE due its rate-limiting dissolution, poor bioavailability, significant food effect. Both were shown facilitate lurasidone supersaturation within vitro dissolution studies simulating gastrointestinal environment. This translated into profound improvements pharmacokinetics rats, exerting comparable ∼ 2.5-fold compared pure drug. imparted contrasting effects microbiota, depleting richness abundance microbial ecosystem, as evidenced through reductions alpha diversity (Chao1 index) operational taxonomical units (OTUs). In contrast, exerted 'gut neutral' effect, whereby mild enrichment OTUs observed. Importantly, suggests ASDs are effective solubility-enhancing can be used without comprising integrity – integral consideration treatment mental health disorders, such schizophrenia, role regulating mood cognition.

Language: Английский

Citations

0
Therapeutic Potential of Inulin‐Coated MCT Microcapsules in Modulating the Gut Microbiome for Effective Treatment of Diet‐Induced Obesity DOI Creative Commons
Amin Ariaee, Hannah R. Wardill, Anthony Wignall

et al.

Advanced Therapeutics, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 9, 2024

Abstract Obesity, a global epidemic, leads to metabolic dysregulation and systemic inflammation. Recently, therapies targeting the gut microbiome have garnered attention for health regulation. This study evaluates potential of inulin‐coated medium‐chain triglyceride (InuMCT) microcapsules in rats with diet‐induced obesity (DIO). Inulin prebiotic fibers been shown promote microbiome, while digestion products medium chain triglycerides (MCTs), free fatty acids, mono‐/diglycerides, can attenuate pro‐inflammatory outcomes. It is hypothesized that encapsulating MCTs within inulin via spray drying creates solid dosage form exert multifunctional effects ameliorating inflammation DIO. InuMCT treatments not only reduce DIO weight gain but also improve markers high‐fat diet (HFD) fed rats. Specifically, attenuates reduction high‐density lipoprotein (HDL) by 55% lowers glucose levels 21%. Meanwhile, increases HDL 23% reduces 15%. Furthermore, decreases serum proinflammatory tumor necrosis factor‐alpha (TNF‐α) 35%, further TNF‐α normal 21 days. These results highlight InuMCT's superior efficacy, offering promising strategy combating related diseases.

Language: Английский

Citations

0